NFIL3 in CAR-T Cell Exhaustion: From IL-2/JAK-STAT5 Signaling Through Chromatin Remodeling to TIM-3 Upregulation
NFIL3 converts chronic IL-2 signaling into T-cell exhaustion by recruiting G9a, SUV39H1, and EZH2 to silence effector genes and drive TIM-3 in CAR-T cells.
Molecular Pathway Insights
NFIL3 in CAR-T Cell Exhaustion: From IL-2/JAK-STAT5 Signaling Through Chromatin Remodeling to TIM-3 Upregulation
CAR-T cell therapy fails when chronic antigen exposure locks engineered T cells into a terminally exhausted state. The transcription factor NFIL3 (E4BP4) sits at the centre of this collapse: induced by IL-2 via JAK-STAT5, it recruits repressive histone methyltransferases to silence effector and memory programmes while directly driving TIM-3 expression. This pathway analysis traces the molecular cascade from receptor signaling through chromatin remodeling to effector function loss.
Pathogenic origin of NFIL3-driven CAR-T cell exhaustion
CAR-T cell exhaustion emerges from the convergence of three mechanistic forces: chronic IL-2/JAK-STAT5 signaling that induces the transcriptional repressor NFIL3, epigenomic reprogramming through recruitment of histone-modifying enzymes (G9a, SUV39H1, EZH2), and a parallel TOX/NFAT2 axis that coordinates the broader exhaustion landscape through HBO1-dependent chromatin acetylation (PMID: 38056892; PMID: 31207603). These pathways are not sequential but concurrent; tonic CAR signaling and antigen-dependent stimulation both feed into NFIL3 induction, creating a dual-input system that accelerates the transition from functional effector to terminally exhausted T cell (PMID: 39438476). The pathogenic origin is therefore not a single molecular event but a convergence of receptor hyperstimulation, transcription factor induction, and chromatin lock-in that collectively render CAR-T cells refractory to checkpoint blockade.
Molecular mechanism of NFIL3-mediated epigenetic silencing in T-cell exhaustion
The induction of NFIL3 begins at the IL-2 receptor. High-affinity IL-2R engagement (including the IL-2R alpha chain CD25) triggers JAK1/JAK3 phosphorylation of STAT5, which translocates to the nucleus and binds the Nfil3 promoter to drive its transcription (PMID: 38056892). In T cells with enhanced IL-2 responsiveness (such as those with PTPN22 deletion), this signaling loop is amplified, producing supraphysiological levels of NFIL3 that correlate with accelerated exhaustion and earlier TIM-3 surface expression. NFIL3 then binds directly to regulatory regions of the Havcr2 locus (encoding TIM-3) to promote its transcription, distinguishing TIM-3 regulation from PD-1 and TIGIT, which are controlled by distinct transcriptional programmes (PMID: 38056892).
Once expressed, NFIL3 (E4BP4) acts as a scaffold for repressive chromatin modification. It recruits the histone methyltransferases G9a (EHMT2) and SUV39H1 to target gene promoters, where they catalyse mono- and trimethylation of H3K9, establishing a repressive chromatin state that silences genes including the RAS effector RASSF8 (PMID: 29467226). In parallel, E4BP4 recruits HDAC1 (histone deacetylase 1) and EZH2 (the catalytic subunit of PRC2) to enforce additional layers of silencing: HDAC1 removes activating acetyl marks while EZH2 deposits H3K27me3 at target promoters, as demonstrated in the context of Bcl6 regulation during T follicular helper cell differentiation (PMID: 32191636). The convergence of H3K9me (via G9a/SUV39H1), histone deacetylation (via HDAC1), and H3K27me3 (via EZH2) produces a multi-layered repressive state at loci encoding effector cytokines, memory transcription factors, and survival receptors.
Operating in parallel, the TOX/NFAT2 axis reinforces the exhaustion programme at the epigenomic level. Persistent TCR-driven Ca2+ flux sustains NFATc1 (NFAT2) activity, which induces Tox transcription. TOX then enters a calcineurin-independent feed-forward loop, recruiting the HBO1 complex (containing the acetyltransferase Kat7) to coordinate histone acetylation at exhaustion-associated enhancers while closing accessibility at memory loci such as Tcf7, Slamf6, and Il7r (PMID: 31207603). Meanwhile, DNMT3A deposits de novo DNA methylation at Ifng and Tcf7, sealing the silencing programme at the DNA level (PMID: 38582965). The NFIL3 and TOX axes therefore converge on overlapping target loci through complementary epigenetic mechanisms: NFIL3 installs repressive histone marks while TOX remodels chromatin accessibility and DNMT3A locks in DNA methylation.
Cellular and molecular damage from NFIL3-mediated chromatin remodeling in CAR-T cells
The cellular consequences of NFIL3-mediated chromatin remodeling manifest as a hierarchical loss of T-cell effector and memory functions. At the chromatin level, the H3K9me marks deposited by G9a and SUV39H1 at effector gene promoters create a barrier that resists transcriptional reactivation even upon checkpoint blockade. The additional H3K27me3 layer (via EZH2) and deacetylation (via HDAC1) reduce chromatin accessibility at loci encoding IFN-gamma, TNF, and IL-2, directly impairing polyfunctionality. In CAR-T cells experiencing tonic signaling, these repressive marks accumulate progressively, correlating with the transition from the TCF1+ progenitor exhausted state through the intermediate state to the TIM-3 high, TCF1 negative terminally exhausted phenotype (PMID: 38582965; PMID: 32396847).
At the cell-surface level, NFIL3-driven TIM-3 upregulation marks the commitment to terminal exhaustion. Unlike PD-1, which is expressed across multiple exhaustion states, TIM-3 (encoded by Havcr2) is specifically associated with the loss of self-renewal capacity and the inability to respond to anti-PD-1 therapy. In adoptive transfer models, Ptpn22-deleted CAR-T cells showed enhanced initial cytotoxicity but earlier and higher TIM-3 expression, leading to more rapid effector function loss and impaired long-term tumour control (PMID: 38056892). The MAPK/AP-1 axis compounds this damage: chronic CAR signaling activates MEK, which drives c-Fos and JunB expression, transcription factors that promote terminal differentiation gene programmes and apoptosis (PMID: 39438476). TOX simultaneously antagonises T-bet expression, shifting the transcriptional balance away from effector function and toward the exhaustion programme (PMID: 32396847).
Downstream pathophysiological outcome: a self-reinforcing exhaustion circuit in CAR-T cells
The NFIL3 pathway establishes a feed-forward circuit in which chronic IL-2 signaling induces NFIL3, NFIL3 recruits G9a/SUV39H1/EZH2/HDAC1 to silence effector and memory genes, the resulting loss of IL-2 production capacity shifts the T cell toward dependence on paracrine IL-2, and continued IL-2R engagement sustains NFIL3 expression. In parallel, NFIL3-driven TIM-3 upregulation marks the cell for terminal exhaustion, while the TOX/NFAT2 axis closes memory-associated chromatin and DNMT3A seals the silencing with DNA methylation. Pharmacological intervention at the MEK node (trametinib at 15 nM reduces JunB-driven exhaustion programmes; PMID: 39438476) or through transient rest (dasatinib-mediated signaling cessation triggers EZH2-dependent epigenetic reprogramming and restores 60% polyfunctionality; PMID: 33795428) can partially interrupt this circuit, but the H3K9me marks deposited by G9a and SUV39H1 under NFIL3 direction represent a particularly durable epigenetic scar whose reversal remains an open therapeutic challenge.
Frequently asked questions
What is NFIL3 and what role does it play in CAR-T cell exhaustion?
NFIL3 (also called E4BP4) is a basic leucine zipper transcription factor induced by IL-2 signaling via the JAK-STAT5 axis. In CAR-T cells under chronic stimulation, NFIL3 recruits repressive histone methyltransferases (G9a, SUV39H1) and the PRC2 component EZH2 to silence effector and memory genes while promoting expression of the exhaustion marker TIM-3.
How does NFIL3 drive TIM-3 expression in exhausted T cells?
NFIL3 binds the Havcr2 (TIM-3) locus and promotes its transcription downstream of IL-2 signaling. This distinguishes TIM-3 regulation from other inhibitory receptors like PD-1 or TIGIT, which are controlled through distinct transcriptional programmes.
What histone modifications does NFIL3 recruit to silence T-cell effector genes?
NFIL3 recruits G9a and SUV39H1, which catalyse repressive H3K9 methylation at target promoters. It also recruits HDAC1 and EZH2 (the catalytic subunit of PRC2), which mediate histone deacetylation and H3K27 trimethylation respectively, reinforcing transcriptional silencing.
How does the TOX-NFAT axis interact with NFIL3 in T-cell exhaustion?
Sustained NFAT2 (NFATc1) activity under chronic TCR signaling induces TOX expression. TOX then coordinates epigenetic remodeling via the HBO1 complex. NFIL3 operates in a parallel but converging axis: while TOX programs the broad exhaustion landscape, NFIL3 specifically enforces TIM-3 expression and recruits H3K9-silencing enzymes to effector loci.
Can MEK inhibition or transient rest reverse NFIL3-mediated CAR-T exhaustion?
MEK inhibition with trametinib reduces AP-1 factors c-Fos and JunB, preventing terminal differentiation and enhancing in vivo CAR-T efficacy. Transient rest via dasatinib triggers EZH2-dependent epigenetic reprogramming that restores polyfunctionality. Whether these interventions fully reverse NFIL3-specific H3K9 silencing marks remains under investigation.
What is the difference between progenitor, intermediate, and terminally exhausted T cells?
Exhausted CD8+ T cells exist on a developmental continuum: TCF1+ progenitor cells retain self-renewal and respond to checkpoint blockade; intermediate cells express both effector and inhibitory markers; terminally exhausted cells (TIM-3 high, TCF1 negative) have lost proliferative capacity and effector function. NFIL3 activity accelerates the transition toward the terminal state.
Is the epigenetic scarring caused by NFIL3 reversible in CAR-T cells?
Current evidence suggests that H3K9me marks deposited by G9a and SUV39H1 are difficult to reverse. PD-1 blockade alone does not erase these epigenetic scars. However, transient rest combined with EZH2-dependent remodeling has shown partial restoration of function, suggesting that the timing of intervention relative to NFIL3 activation may determine reversibility.
Trace the molecular cascade from receptor to chromatin with PubMed-verified evidence
BioSkepsis grounds every claim in verified PubMed records. Run your own pathway analysis on NFIL3, TOX, or any molecular target in the exhaustion programme.
Start freeSources and further reading
- Teagle AR, Castro-Sanchez P, Brownlie RJ, et al. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion. J Immunother Cancer. 2023;11(12). PMID: 38056892. DOI
- Karthik IP, Desai P, Sukumar S, et al. E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 function through histone methyltransferases. J Biol Chem. 2018;293(15):5624-5635. PMID: 29467226. DOI
- Wang Z, Zhao M, Yin J, et al. E4BP4-mediated inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases. J Clin Invest. 2020;130(7):3717-3733. PMID: 32191636. DOI
- Wang X, Tao X, Chen P, et al. MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. Signal Transduct Target Ther. 2024;9(1):293. PMID: 39438476. DOI
- Weber EW, Parker KR, Sotillo E, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021;372(6537):eaba1786. PMID: 33795428. DOI
- Ahn T, Bae EA, Seo H. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Mol Ther. 2024;32(6):1617-1627. PMID: 38582965. DOI
- Khan O, Giles JR, McDonald S, et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature. 2019;571(7764):211-218. PMID: 31207603. DOI